Robert Pecha, MD
Gastroenterology · Placerville, CANPI 1619918133
Payments from drug & device makers
Across 611 payments — averaging $20.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Johnson & Johnson$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Sanofi$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$977
- Pfizer$429
- plus $3K from 31 others
What the payments were for
- Food & beverage$12,36398%
- Education$3032%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 210 | $4,380 |
| Johnson & Johnson | 81 | $1,580 |
| Takeda Pharmaceuticals U.S.A., Inc. | 54 | $1,030 |
| Sanofi | 40 | $1,026 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 53 | $977 |
| Pfizer | 25 | $429 |
| Madrigal Pharmaceuticals | 9 | $417 |
| QOL Medical, LLC | 24 | $392 |
| Gilead | 16 | $286 |
| Regeneron Healthcare Solutions, Inc. | 12 | $272 |
| Bristol Myers Squibb | 11 | $250 |
| Merck | 14 | $221 |
| Nestle Healthcare Nutrition Inc. | 6 | $166 |
| Intercept Pharmaceuticals, Inc. | 3 | $138 |
| Ipsen Biopharmaceuticals, Inc | 5 | $125 |
| Boston Scientific | 4 | $122 |
| Aimmune Therapeutics, Inc. | 3 | $101 |
| Daiichi Sankyo Inc. | 4 | $87 |
| Braintree Laboratories, Inc. | 5 | $78 |
| Ironwood Pharmaceuticals, Inc | 4 | $64 |
| Olympus America Inc. | 3 | $55 |
| Ardelyx, Inc. | 3 | $50 |
| Phathom Pharmaceuticals, Inc. | 2 | $48 |
| Ferring Pharmaceuticals Inc. | 3 | $46 |
| Lilly USA, LLC | 2 | $45 |
| Exact Sciences | 2 | $37 |
| Fujifilm Healthcare Americas Corporation | 1 | $37 |
| Organon | 2 | $34 |
| Alfasigma USA, Inc. | 2 | $28 |
| Biocon Biologics Inc | 1 | $28 |
| UCB, Inc. | 1 | $22 |
| Vivus LLC | 1 | $21 |
| Celltrion USA Inc. | 1 | $18 |
| Shionogi Inc | 1 | $16 |
| AstraZeneca | 1 | $13 |
| Boehringer Ingelheim | 1 | $13 |
| Medline Industries LP | 1 | $12 |
How this compares
$12,667 in reported general payments places this provider in the 75th percentile of 1,885 gastroenterology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 24 | $604,141 |
| Humira PenAdalimumab | 26 | $246,302 |
| Entyvio PenVedolizumab | 12 | $75,496 |
| MotegrityPrucalopride Succinate | 38 | $39,093 |
| CreonLipase/Protease/Amylase | 24 | $37,428 |
| Mesalamine | 58 | $24,558 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 131 | $21,140 |
| LinzessLinaclotide | 15 | $11,993 |
| Budesonide EcBudesonide | 54 | $8,665 |
| Famotidine | 489 | $7,743 |
| Mesalamine ErMesalamine | 14 | $7,582 |
| Ursodiol | 19 | $7,280 |
| CholestyramineCholestyramine (With Sugar) | 87 | $6,695 |
| Pantoprazole Sodium | 398 | $5,866 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 85 | $5,568 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $1,580 | $604,14124 claims |
| AbbVieCreon, Linzess | $4,380 | $49,42139 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $1,030 | $39,09338 claims |
| Braintree Laboratories, Inc.Sutab | $78 | $21,140131 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,885 gastroenterology providers in California.
Other gastroenterology in Placerville
- Peter WinkleCypress$116.7M
- Manuchehr DaraniSanta Ana$17.7M
- Jatinder PruthiLancaster$4.4M
- Long DangWestminster$4.3M
- Muhammad SheikhFresno$4.3M
- Gregory WienerChula Vista$3.5M
- Gil MelmedLos Angeles$3M
- Christopher BowlusSacramento$3M
- Bennett RothLos Angeles$2.8M
- Brigid BolandSan Diego$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.